Niaspan
Niaspan Antitrust Litigation belongs to the reverse-payment, or pay-for-delay, category of pharmaceutical antitrust cases: purchasers allege that the brand manufacturer of this cholesterol medication compensated a would-be generic competitor to stay out of the market for a period of time, extending the brand's monopoly pricing beyond what ordinary patent litigation would have produced. Centralized in the Eastern District of Pennsylvania in 2013, the docket carries 20 pending actions and sits within a well-developed body of federal antitrust law on how reverse-payment settlements are evaluated.
What drives resolution risk in this specific docket is less about the general legal framework — courts have applied a rule-of-reason analysis to reverse-payment settlements for over a decade — and more about drug-specific and purchaser-specific facts: the size and terms of the alleged payment, the strength of the underlying patent dispute the payment resolved, and the counterfactual timeline for generic entry absent the settlement. Those facts drive both the liability analysis and, separately, the damages model for each purchaser class, and they are litigated largely independent of how similar reverse-payment matters for other drugs have resolved.
For anyone tracking how pharmaceutical antitrust MDLs move through the federal system, Niaspan is a representative example of the reverse-payment category: a legal theory with a mature doctrinal foundation applied to drug-specific facts that still require individualized proof. Criterica Intelligence's platform tracks this distinction — settled legal doctrine versus case-specific factual development — across every active MDL, which is a more precise duration signal than treating "pharmaceutical antitrust" as a single undifferentiated category.
It's a claim that a brand drug manufacturer paid a generic competitor to delay entering the market, extending the brand's monopoly pricing period. Courts apply a rule-of-reason analysis to these settlements, weighing the payment against the underlying patent dispute it resolved.
Well established. Federal courts have applied a rule-of-reason framework to reverse-payment settlements for over a decade, so this docket largely turns on drug-specific and purchaser-specific facts rather than an unresolved question of law.
The size and terms of the alleged payment, the strength of the underlying patent dispute it resolved, and the counterfactual timeline for generic entry absent the settlement — these drive both liability and the purchaser-specific damages model.
It represents the reverse-payment category specifically — a mature legal doctrine applied to drug-specific facts — which behaves differently from pharmaceutical antitrust claims based on novel theories. Criterica Intelligence distinguishes these categories rather than treating them as one.
Statistics shown reflect historical or illustrative model outputs derived from real case data. They are not predictions or guarantees of any individual outcome. Litigation results depend on facts, jurisdiction, judge, and counsel, and vary case by case. Model accuracy is subject to selection effects and changing legal dynamics.